Ultrasound Report Interpretation - 80-Year-Old Male with Dysuria (Burning Urination)

Findings Summary

Report 1

Report 2

Detailed Clinical Interpretation

1. Benign Prostatic Hyperplasia (BPH) - Grade II / Prostatomegaly

• Normal prostate volume in an adult male is 20-30 cc. This patient's prostate measures 44-49 cc - approximately 1.5 to 2x the normal size
• This qualifies as Grade II BPH (moderate enlargement)
• The enlarged prostate causes bladder outlet obstruction (BOO), leading to:
  • Incomplete bladder emptying
  • Increased intravesical pressure
  • Bladder wall hypertrophy (explaining the 5 mm wall thickening seen in Report 1; normal is < 3-4 mm in a full bladder)
  • Urinary stasis favoring bacterial colonization

2. Cystitis (Bladder Infection)

• The bladder wall thickening to 5 mm and low-level internal echoes within the bladder on USG are classic sonographic signs of cystitis (inflammatory/infective thickening of the bladder mucosa)
• In this patient, cystitis is secondary to BPH - the enlarged prostate leads to urinary stasis and incomplete voiding, which provides a fertile medium for bacterial growth
• As per Campbell-Walsh Urology: "acute onset of dysuria and acute change in baseline voiding symptoms are most consistent with a diagnosis of acute uncomplicated cystitis" - exactly this patient's presentation
• In elderly men, the most common pathogens are E. coli, Klebsiella, Proteus (gram-negative rods)
• Important note: UTI/cystitis in men is considered complicated UTI (unlike women) because there is almost always an underlying structural or functional cause (here: BPH with urinary stasis)

3. Post-Void Residual Urine (PVRU) = 35.9 cc

• Normal PVRU is < 50 cc. A value of 35.9 cc is technically within borderline range, but the report labels it "significant" in the clinical context of prostatomegaly
• Elevated PVRU confirms incomplete bladder emptying due to BPH obstructing outflow
• Persistent PVRU predisposes to recurrent UTIs and, if untreated, can progress to bladder decompensation, hydronephrosis, and renal impairment

4. Right Renal Simple Cortical Cyst - Bosniak Grade I

• A Bosniak Grade I cyst is a simple benign cyst - thin-walled, anechoic, no septations, no solid components
• No treatment or follow-up required for Bosniak I
• Not related to urinary symptoms

5. Grade II Fatty Liver (Hepatic Steatosis)

• Incidental finding; moderate hepatic fat infiltration
• Not related to the presenting complaint of burning urination
• May warrant metabolic workup (lipid profile, blood glucose, liver function tests)

Clinical Correlation and Recommended Next Steps

Summary for the Patient's Family

This 80-year-old gentleman has an enlarged prostate (~1.5-2x normal size) that is blocking normal urine flow. Urine is not fully emptying from the bladder, and this stagnant urine has developed a bladder infection - which is causing the burning sensation. There is also a harmless fluid cyst on the right kidney and mild fatty changes in the liver (unrelated to urinary symptoms). He needs antibiotics for the infection (guided by urine culture) and medications for the enlarged prostate to prevent recurrence. A urology consultation is recommended.

Treatment Plan: BPH + UTI (Cystitis) in an 80-Year-Old Male

PART 1 - Treating the UTI (Immediate Priority)

Why this is a Complicated UTI

Step 1 - Urine Culture First

• Send urine for routine microscopy + culture & sensitivity (C&S) before starting antibiotics (ideally midstream clean-catch)
• Start empiric antibiotics simultaneously; adjust once C&S report is available (48-72 hrs)

Step 2 - Antibiotic Selection

Important: Check eGFR/creatinine before prescribing - dose-adjust ciprofloxacin if eGFR < 30 mL/min.

Step 3 - Supportive Measures

• Oral hydration - increase fluid intake to 2-3 L/day to flush bacteria
• Urinary analgesic - Phenazopyridine 200 mg TDS for 1-2 days for immediate symptom relief (turns urine orange - warn the patient)
• Avoid catheterization unless urinary retention develops - catheters increase risk of resistant organisms

PART 2 - Treating BPH (Prostate Volume ~44-49 cc, Grade II)

Drug Class Comparison (from Lippincott Pharmacology)

Drug 1 - Alpha-1 Blocker (Start immediately - symptom relief in 2-4 weeks)

• Mechanism: Blocks alpha-1A receptors in prostatic smooth muscle → relaxes urethral resistance → better urine flow
• Most suitable for an 80-year-old because it is prostate-selective (alpha-1A > alpha-1B) - minimal blood pressure drop compared to doxazosin or terazosin (critical in elderly at risk of orthostatic hypotension and falls)
• Onset: symptom relief in 2-4 weeks
• Side effects to counsel: retrograde ejaculation, dizziness, nasal congestion
• Caution - Intraoperative Floppy Iris Syndrome (IFIS): If this patient ever needs cataract surgery, inform the ophthalmologist that he is on tamsulosin

Alternative: Alfuzosin 10 mg OD (also prostate-selective, possibly fewer ejaculatory side effects)

Drug 2 - 5-Alpha Reductase Inhibitor (Long-term prostate shrinkage - takes 6-12 months)

• Mechanism: Inhibits conversion of testosterone → DHT (dihydrotestosterone). DHT drives prostate growth. By reducing DHT, the prostate physically shrinks over time (typically 20-30% reduction)
• Finasteride takes 6-12 months for full effect; dutasteride is more potent (inhibits both type 1 and type 2 5-alpha reductase)
• Only effective when prostate is enlarged - this patient qualifies (44-49 cc vs normal 20-30 cc)
• Side effects: decreased libido, erectile dysfunction, gynecomastia, reduced ejaculate volume
• Important PSA note: 5-alpha reductase inhibitors reduce PSA by ~50% after 6 months. The baseline PSA must be checked before starting and then multiplied by 2 when interpreting future PSA values to screen for prostate cancer

Combination Therapy

• The MTOPS trial and CombAT trial established that combination therapy (tamsulosin + dutasteride) is superior for prostate volumes >40 cc
• A fixed-dose combination is available: Duodart (dutasteride 0.5 mg + tamsulosin 0.4 mg) once daily for convenience

When to Consider Surgery (TURP)

• Symptoms do not improve after 3-6 months of combination medical therapy
• Progressive increase in PVRU (>200 cc)
• Acute urinary retention (inability to void)
• Recurrent UTIs due to urinary stasis
• Hydronephrosis develops on repeat ultrasound

Summary Drug Chart for This Patient

Monitoring Plan

This information is for clinical education. All prescribing decisions must be made by the treating physician after full patient evaluation.